Winning With Four: Hemodynamic and Symptomatic Improvement of Pulmonary Arterial Hypertension With Contemporary Quadruple Therapy
Abstract
Background: Pulmonary arterial hypertension (PAH) is a progressive disease characterized by high morbidity and mortality. We present a case highlighting significant clinical improvement of severe PAH with severe right ventricular dysfunction with contemporary quadruple PAH therapies.
Case presentation: A 68-year-old man presented with exertional dyspnea and hypoxia. Right heart catheterization confirmed precapillary pulmonary hypertension with right ventricular dysfunction and low cardiac output. Initial upfront traditional triple therapy with uptitration of treprostinil led to modest improvement. After Food and Drug Administration approval, addition of sotatercept further significantly improved hemodynamics, right ventricular function, biomarkers, and functional status.
Discussion: This case highlights the evolving management of PAH and the importance of rapid diagnosis. Initiation of quadruple therapy with monitoring was key to the remarkable improvement in symptoms and objective parameters seen in our patient.
Take-home message: Managing pulmonary arterial hypertension in patients with multiple comorbidities is challenging and requires a multidisciplinary approach with aggressive upfront therapy leading to significant symptomatic and hemodynamic improvement.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.